Page 1

BIOSYENT RELEASES Q3 AND YTD 2021 FINANCIAL RESULTS ● ● FOR IMMEDIATE RELEASE MISSISSAUGA , ONTARIO ( November 18 , 2021 ) BioSyent Inc. ( " BioSyent " , TSX Venture : RX ) released today its financial results for the three and nine months ended September 30 , 2021. Key highlights include : ● BioSyent ● ● NEWS RELEASE NOVEMBER 18 , 2021 Third quarter ( Q3 ) 2021 Net Revenues of $ 6,690,419 increased by 16 % versus Q3 2020 Year - to - date ( YTD ) 2021 Net Revenues of $ 21,399,562 increased by 29 % versus YTD 2020 Canadian Pharmaceutical Net Revenues in Q3 2021 of $ 6,409,809 increased by 17 % versus Q3 2020 YTD 2021 Canadian Pharmaceutical Net Revenues of $ 19,313,894 increased by 22 % versus YTD 2020 Q3 2021 International Pharmaceutical Net Revenues of $ Nil as compared to $ 6,306 in Q3 2020 YTD 2021 International Pharmaceutical Net Revenues of $ 1,305,317 increased by 675 % versus YTD 2020 Q3 2021 EBITDA¹ of $ 2,293,713 increased by 64 % versus Q3 2020 YTD 2021 EBITDA¹ of $ 6,144,581 increased by 38 % versus YTD 2020 Q3 2021 Net Income After Taxes ( NIAT ) of $ 1,721,320 increased by 80 % versus Q3 2020 YTD 2021 NIAT of $ 4,403,762 increased by 41 % versus YTD 2020 Q3 2021 NIAT percentage to Net Revenues of 26 % compares to 17 % in Q3 2020 YTD 2021 NIAT percentage to Net Revenues of 21 % compares to 19 % in YTD 2020 Q3 2021 Fully Diluted EPS of $ 0.13 was $ 0.06 higher than Q3 2020 Fully Diluted EPS of $ 0.07 YTD 2021 Fully Diluted EPS of $ 0.34 was $ 0.10 higher than YTD 2020 Fully Diluted EPS of $ 0.24 Fully Diluted EPS for the Trailing Twelve Months ended September 30 , 2021 was $ 0.39 as compared to $ 0.32 for the Trailing Twelve Months ended September 30 , 2020 As at September 30 , 2021 , the Company had cash , cash equivalents , and short - term investments totalling $ 27,101,933 , a 6 % increase as compared to $ 25,577,706 as at December 31 , 2020 Total Shareholders ' Equity increased by 13 % to $ 30,332,390 at September 30 , 2021 from $ 26,795,956 at December 31 , 2020 Return on Equity for the Trailing Twelve Months ended September 30 , 2021 was 18 % as compared to 17 % for the Trailing Twelve Months ended September 30 , 2020 During YTD 2021 , repurchased and cancelled a total of 79,700 common shares under a Normal Course Issuer Bid ( NCIB ) " Q3 2021 marked BioSyent's 45th consecutive profitable quarter as well as its most profitable quarter to date with record NIAT of $ 1,721,320 increasing by 80 % over Q3 2020. Our established Canadian pharmaceutical brands , led by FeraMAX® Pd , continued to drive topline growth and profitability while we continued to invest in launch brands , resulting in a healthy 26 % net profit margin overall in the quarter . Together with growth contributed by launch brands , Tibella® and Combogesic® , Canadian pharmaceutical sales showed double - digit growth overall for the quarter as we navigated through the ongoing impacts of COVID - 19 on the business and healthcare environments in Canada , " commented Mr. René Goehrum , President and CEO of BioSyent . " We generated $ 2.3 million of cash during Q3 2021 and have maintained our commitment to our NCIB , having bought back 142,650 shares to date during 2021. In October of this year , we launched FeraMAX® Pd Powder 15 , the second product using the patented PDIC oral iron delivery system , following on the success of FeraMAX® Pd Therapeutic 150 , launched in November 2020. We are planning for further